RP-661, a novel small molecule, demonstrates significant protection across a range of acute and chronic seizure models, positioning it as a promising therapeutic alternative for patients with drug-resistant epilepsy.
About LRP-661: LRP-661 is the lead compound in London Research & Pharmaceuticals’ portfolio. It represents an orally available, cannabidiol sulphate ester, with predictable dosing and formulation offering promising prospects for epilepsy treatment. With the only currently available prescription formulation of cannabidiol being a sesame oil suspension marketed as Epidiolex® (a registered trademark of Jazz Pharma), which achieved sales of $845 million in 2023, LRP-661 may emerge as a potential disrupter in the field of epilepsy therapeutics.
About London Research & Pharmaceuticals: London Research & Pharmaceuticals is dedicated to synthesizing highly druggable formulations of existing compounds, with a focus on addressing unmet medical needs. In addition to LRP-661, the company has generated preclinical data on various compounds targeting a spectrum of diseases, including inflammation, nerve pain, infectious diseases, and oncology. London Research & Pharmaceuticals remains open to partnership discussions for its proprietary compounds as it continues to drive innovation in drug discovery and development.